Erratum: Cell-to-cell transmission of non-prion protein aggregates (Nature Reviews Neurology (2010) 6 (702-706) DOI: 10.1038/nrneurol.2010.145));Cell-to-cell transmission of non-prion protein aggregates

Nature Reviews Neurology

Volumn 6, Issue 12, 2010, Pages 702-706

  Lee, Seung Jae ^a   Desplats, Paula ^b   Sigurdson, Christina ^b   Tsigelny, Igor ^b   Masliah, Eliezer ^b  

^a Konkuk University   (South Korea)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA SYNUCLEIN; AMYLOID A PROTEIN; AMYLOID BETA PROTEIN; AMYLOID PRECURSOR PROTEIN; APOLIPOPROTEIN A2; HUNTINGTIN; POLYGLUTAMINE; TAU PROTEIN;

ALZHEIMER DISEASE; AMYLOIDOSIS; BOVINE SPONGIFORM ENCEPHALOPATHY; CONFORMATIONAL TRANSITION; CREUTZFELDT JAKOB DISEASE; CYTOSOL; HUMAN; INTRACELLULAR TRANSPORT; NERVE DEGENERATION; NERVE FIBER TRANSPORT; NONHUMAN; PARKINSON DISEASE; PRION DISEASE; PRIORITY JOURNAL; PROTEIN AGGREGATION; PROTEIN FOLDING; PROTEIN POLYMERIZATION; PROTEIN SYNTHESIS; REVIEW;

EID: 78649907008     PISSN: 17594758     EISSN: 17594766     Source Type: Journal    
DOI: 10.1038/nrneurol.2010.191     Document Type: Erratum

References (43)

1. Forman, M. S., Trojanowski, J. Q. & Lee, V. M. Neurodegenerative diseases: a decade of discoveries paves the way for therapeutic breakthroughs. Nat. Med. 10, 1055-1063 (2004).
2. Lansbury, P. T. & Lashuel, H. A. A century-old debate on protein aggregation and neurodegeneration enters the clinic. Nature 443, 774-779 (2006).
3. Glabe, C. G. Structural classification of toxic amyloid oligomers. J. Biol. Chem. 283, 29639-29643 (2008).
4. Tsigelny, I. F. et al. Mechanisms of hybrid oligomer formation in the pathogenesis of combined Alzheimer's and Parkinson's diseases. PLoS ONE 3, e3135 (2008).
5. Aguzzi, A., Baumann, F. & Bremer, J. The prion's elusive reason for being. Annu. Rev. Neurosci. 31, 439-477 (2008).
6. Braak, H. & Braak, E. Neuropathological stageing of Alzheimer-related changes. Acta Neuropathol. 82, 239-259 (1991).
7. Braak, H. et al. Staging of brain pathology related to sporadic Parkinson's disease. Neurobiol. Aging 24, 197-211 (2003).
8. Solomon, A. et al. Amyloidogenic potential of foie gras. Proc. Natl Acad. Sci. USA 104, 10998-11001 (2007).
9. Sponarova, J., Nystrom, S. N. & Westermark, G. T. AA-amyloidosis can be transferred by peripheral blood monocytes. PLoS ONE 3, e3308 (2008).
10. Ross, C. A. & Poirier, M. A. Protein aggregation and neurodegenerative disease. Nat. Med. 10 (Suppl.), S10-S17 (2004).
11. Jarrett, J. T. & Lansbury, P. T. Jr. Seeding "onedimensional crystallization" of amyloid: a pathogenic mechanism in Alzheimer's disease and scrapie? Cell 73, 1055-1058 (1993).
12. Petkova, A. T. et al. Self-propagating, molecularlevel polymorphism in Alzheimer's β-amyloid fibrils. Science 307, 262-265 (2005).
13. Yonetani, M. et al. Conversion of wild-type α-synuclein into mutant-type fibrils and its propagation in the presence of A30P mutant. J. Biol. Chem. 284, 7940-7950 (2009).
14. Frost, B., Ollesch, J., Wille, H. & Diamond, M. I. Conformational diversity of wild-type Tau fibrils specified by templated conformation change. J. Biol. Chem. 284, 3546-3551 (2009).
15. Frost, B., Jacks, R. L. & Diamond, M. I. Propagation of tau misfolding from the outside to the inside of a cell. J. Biol. Chem. 284, 12845-12852 (2009).
16. Ren, P. H. et al. Cytoplasmic penetration and persistent infection of mammalian cells by polyglutamine aggregates. Nat. Cell Biol. 11, 219-225 (2009).
17. Luk, K. C. et al. Exogenous α-synuclein fibrils seed the formation of Lewy body-like intracellular inclusions in cultured cells. Proc. Natl Acad. Sci. USA 106, 20051-20056 (2009).
18. Meyer-Luehmann, M. et al. Exogenous induction of cerebral β-amyloidogenesis is governed by agent and host. Science 313, 1781-1784 (2006).
19. Kotzbauer, P. T. et al. Fibrillization of α-synuclein and tau in familial Parkinson's disease caused by the A53T α-synuclein mutation. Exp. Neurol. 187, 279-288 (2004).
20. Morales, R. et al. Molecular cross talk between misfolded proteins in animal models of Alzheimer's and prion diseases. J. Neurosci. 30, 4528-4535 (2010).
21. Balch, W. E., Morimoto, R. I., Dillin, A. & Kelly, J. W. Adapting proteostasis for disease intervention. Science 319, 916-919 (2008).
22. Lee, H. J., Patel, S. & Lee, S. J. Intravesicular localization and exocytosis of α-synuclein and its aggregates. J. Neurosci. 25, 6016-6024 (2005).
23. El-Agnaf, O. M. et al. Detection of oligomeric forms of α-synuclein protein in human plasma as a potential biomarker for Parkinson's disease. FASEB J. 20, 419-425 (2006).
24. Vandermeeren, M. et al. Detection of tau proteins in normal and Alzheimer's disease cerebrospinal fluid with a sensitive sandwich enzyme-linked immunosorbent assay. J. Neurochem. 61, 1828-1834 (1993).
25. Lee, H. J. et al. Assembly-dependent endocytosis and clearance of extracellular α-synuclein. Int. J. Biochem. Cell Biol. 40, 1835-1849 (2008).
26. Hu, X. et al. Amyloid seeds formed by cellular uptake, concentration, and aggregation of the amyloid-beta peptide. Proc. Natl Acad. Sci. USA 106, 20324-20329 (2009).
27. Fevrier, B. et al. Cells release prions in association with exosomes. Proc. Natl Acad. Sci. USA 101, 9683-9688 (2004).
28. Gousset, K. et al. Prions hijack tunnelling nanotubes for intercellular spread. Nat. Cell Biol. 11, 328-336 (2009).
29. Legname, G. et al. Continuum of prion protein structures enciphers a multitude of prion isolatespecified phenotypes. Proc. Natl Acad. Sci. USA 103, 19105-19110 (2006).
30. Cirrito, J. R. et al. Synaptic activity regulates interstitial fluid amyloid-β levels in vivo. Neuron 48, 913-922 (2005).
31. Fortin, D. L. et al. Neural activity controls the synaptic accumulation of α-synuclein. J. Neurosci. 25, 10913-10921 (2005).
32. Legname, G. et al. Synthetic mammalian prions. Science 305, 673-676 (2004).
33. Caughey, B. & Baron, G. S. Prions and their partners in crime. Nature 443, 803-810 (2006).
34. Eisele, Y. S. et al. Induction of cerebral β-amyloidosis: intracerebral versus systemic Aβ inoculation. Proc. Natl Acad. Sci. USA 106, 12926-12931 (2009).
35. Clavaguera, F. et al. Transmission and spreading of tauopathy in transgenic mouse brain. Nat. Cell Biol. 11, 909-913 (2009).
36. Desplats, P. et al. Inclusion formation and neuronal cell death through neuron-to-neuron transmission of α-synuclein. Proc. Natl Acad. Sci. USA 106, 13010-13015 (2009).
37. Kordower, J. H., Chu, Y., Hauser, R. A., Freeman, T. B. & Olanow, C. W. Lewy body-like pathology in long-term embryonic nigral transplants in Parkinson's disease. Nat. Med. 14, 504-506 (2008).
38. Li, J. Y. et al. Lewy bodies in grafted neurons in subjects with Parkinson's disease suggest host-to-graft disease propagation. Nat. Med. 14, 501-503 (2008).
39. Mendez, I. et al. Dopamine neurons implanted into people with Parkinson's disease survive without pathology for 14 years. Nat. Med. 14, 507-509 (2008).
40. Brody, D. L. & Holtzman, D. M. Active and passive immunotherapy for neurodegenerative disorders. Annu. Rev. Neurosci. 31, 175-193 (2008).
41. Wyss-Coray, T. et al. Adult mouse astrocytes degrade amyloid-β in vitro and in situ. Nat. Med. 9, 453-457 (2003).
42. Martinez-Vicente, M. & Cuervo, A. M. Autophagy and neurodegeneration: when the cleaning crew goes on strike. Lancet Neurol. 6, 352-361 (2007).
43. Bahr, B. A. & Bendiske, J. The neuropathogenic contributions of lysosomal dysfunction. J. Neurochem. 83, 481-489 (2002).